AstraZeneca will pay up to $ 6 billion for its experimental anticancer drug

British pharmaceutical company AstraZeneca will pay the Japanese Daiichi Sankyo of up to $ 6 billion for an experimental drug DS-1062, used for treatment of malignant tumors. Under the agreement, the initial payment will be $ 1 billion, writes Reuters.

DS-1062 is a promising class of conjugates of monoclonal antibody and drug. In AstraZeneca expects that the drug will be effective in the treatment of lung cancer, breast cancer and other tumor types, which are characterized by the expression of TROP2.

According to analysts JP Morgan, in case of successful registration DS-1062, sales of the drug may be about $ 1 billion a year.

This is not the first cooperation agreement between AstraZeneca and Daiichi Sankyo. In March of 2019, the parties agreed on the development and marketing of anticancer trastuzumab dioxacine, the amount of the payment transaction may reach 6.9 billion dollars. Recently, the FDA approved the drug for the treatment of inoperable or metastatic HER2-positive breast cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]